Crizanlizumab

Crizanlizumab is a monoclonal antibody medication used for the prevention of vaso-occlusive crises in adult and pediatric patients with sickle cell disease. It is specifically designed to target P-selectin, a protein involved in the formation of blood clots that can cause pain and other complications in individuals with sickle cell disease.
By inhibiting P-selectin, crizanlizumab helps to reduce the frequency and severity of sickle cell pain crises, hospitalizations, and the need for blood transfusions. This medication is administered through intravenous infusion and is typically given once every 3 months, as part of a comprehensive treatment plan for managing sickle cell disease.
Crizanlizumab is not a cure for sickle cell disease, but it is an important addition to the available treatment options for this debilitating condition. Healthcare professionals and patients should work together to determine the most appropriate treatment plan, which may include crizanlizumab in combination with other medications and therapies.